Stock events for Vir Biotechnology, Inc. (VIR)
In the past six months, Vir Biotechnology's stock has trended upward by 81.21%. In February 2026, the company announced a proposed public offering of $200 million of common stock to fund its pipeline. Also in February 2026, Vir Biotechnology reported its Q4 2025 financial results, showing a quarterly loss of $0.31 per share, beating estimates, with revenues of $64.07 million surpassing estimates by 243.23%. A global strategic collaboration with Astellas was announced in February 2026 to advance VIR-5500 for prostate cancer. In December 2023, Vir Biotechnology announced strategic steps to reduce operating expenses, including a workforce reduction of approximately 12% and the consolidation of its geographic footprint, anticipated to result in annual savings of at least $40 million.
Demand Seasonality affecting Vir Biotechnology, Inc.’s stock price
Based on the available information, there is no explicit detail regarding demand seasonality for Vir Biotechnology's specific products and services. Its revenue generation is primarily tied to the advancement of its drug pipeline, collaborations, and potential future commercialization, rather than direct consumer demand for established products that might exhibit seasonal patterns.
Overview of Vir Biotechnology, Inc.’s business
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer by leveraging the immune system. The company operates within the Health Technology sector, specifically in the Biotechnology, Drug Discovery, and Pharmaceuticals industries, with a mission to develop transformative therapies for significant unmet medical needs. Its core strategy involves advancing a focused pipeline of investigational therapies, including the ECLIPSE registrational program for chronic hepatitis delta, PRO-XTEN™ dual-masked T-cell engagers for solid tumors, preclinical candidates targeting influenza A and B antibodies, antibody-drug conjugates, coronavirus monoclonal antibodies, and a preclinical HIV cure program.
VIR’s Geographic footprint
Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California, USA. The company maintains research activities at its San Francisco site and in Bellinzona, Switzerland. In December 2023, Vir Biotechnology announced the closure of its R&D facilities in St. Louis, Missouri, and Portland, Oregon, as part of a strategic effort to consolidate its geographic footprint and reduce operating expenses. The company's offerings are primarily targeted towards healthcare providers and institutions in North America and Europe, with strategic efforts planned for expansion into Asia.
VIR Corporate Image Assessment
Vir Biotechnology experienced a shift in its brand and operational focus after the emergency use authorization for sotrovimab was revoked. In December 2023, the company announced a workforce reduction and the closure of two U.S. facilities to optimize its cost structure. In August 2024, Vir signed a deal with Sanofi to acquire three masked T-cell engagers. The company has emphasized its commitment to advancing its hepatitis delta program and its oncology pipeline. Despite reporting net losses, the company maintains a strong financial position with substantial cash and investments.
Ownership
Vir Biotechnology, Inc. has a mixed ownership structure, with approximately 77.05% of the shares held by institutional owners, 4.06% by insiders, and 62.11% as the float percentage of total shares outstanding. Major institutional owners include BlackRock, Inc., SB Investment Advisers (uk) Ltd, Arch Venture Corp, Vanguard Group Inc, and Glaxosmithkline Plc. SVF Endurance (Cayman) Ltd owns the most shares of Vir Biotechnology.
